SALL4 and gastric cancer: SALL4 is associated with clinicopathological features related to GC progression, and it functions via the Wnt/β-catenin pathway (Yang et al. 2021a), which can be mediated by dual regulation of SALL4 by EZH2 and KDM6A (Ren et al. 2023).